Citadel Advisors
LKFT

Citadel Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Citadel Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.73M Buy
124,428
+35,032
+39% +$1.16M ﹤0.01% 4844
2025
Q4 		$2.92M Buy
89,396
+73,427
+460% +$2.37M ﹤0.01% 5214
2025
Q3 		$553K Buy
15,969
+4,262
+36% +$136K ﹤0.01% 8881
2025
Q2 		$328K Buy
+11,707
New +$314K ﹤0.01% 9598
2025
Q1 		– Sell
-49,373
Closed -$1.25M – 14885
2024
Q4 		$1.36M Sell
49,373
-8,601
-15% -$240K ﹤0.01% 6423
2024
Q3 		$1.67M Sell
57,974
-95,962
-62% -$2.61M ﹤0.01% 5861
2024
Q2 		$3.81M Buy
153,936
+132,439
+616% +$3.76M ﹤0.01% 4180
2024
Q1 		$692K Sell
21,497
-240,887
-92% -$8.96M ﹤0.01% 7691
2023
Q4 		$10.7M Sell
262,384
-207,484
-44% -$7.64M ﹤0.01% 2755
2023
Q3 		$16.2M Buy
469,868
+236,577
+101% +$9.21M ﹤0.01% 2102
2023
Q2 		$9.49M Sell
233,291
-219,827
-49% -$8.97M ﹤0.01% 2744
2023
Q1 		$17.5M Buy
453,118
+117,687
+35% +$4.84M ﹤0.01% 2069
2022
Q4 		$14.9M Buy
335,431
+14,658
+5% +$617K ﹤0.01% 2302
2022
Q3 		$13.7M Buy
320,773
+1,619
+0.5% +$83K ﹤0.01% 2343
2022
Q2 		$17.8M Buy
319,154
+254,162
+391% +$15.1M ﹤0.01% 1973
2022
Q1 		$4.03M Sell
64,992
-455,196
-88% -$27.9M ﹤0.01% 4591
2021
Q4 		$28.7M Buy
520,188
+19,970
+4% +$1.04M 0.01% 1650
2021
Q3 		$26.3M Buy
500,218
+47,039
+10% +$2.79M 0.01% 1690
2021
Q2 		$31.2M Buy
453,179
+161,512
+55% +$12.3M 0.01% 1569
2021
Q1 		$22.5M Buy
291,667
+241,449
+481% +$22.2M 0.01% 1812
2020
Q4 		$4.97M Sell
50,218
-35,450
-41% -$4.33M ﹤0.01% 3697
2020
Q3 		$12.2M Buy
85,668
+57,032
+199% +$9.51M ﹤0.01% 2065
2020
Q2 		$5.65M Buy
28,636
+2,725
+11% +$564K ﹤0.01% 2921
2020
Q1 		$5.08M Sell
25,911
-2,173
-8% -$468K ﹤0.01% 2680
2019
Q4 		$5.81M Buy
28,084
+6,957
+33% +$1.29M ﹤0.01% 2907
2019
Q3 		$3.23M Buy
+21,127
New +$3.46M ﹤0.01% 3735
2019
Q2 		– Sell
-31,516
Closed -$3.74M – 9415
2019
Q1 		$3.71M Buy
31,516
+16,952
+116% +$1.71M ﹤0.01% 3430
2018
Q4 		$1.34M Buy
+14,564
New +$1.48M ﹤0.01% 4831
2018
Q3 		– Sell
-3,566
Closed -$377K – 9390
2018
Q2 		$328K Hold
3,566
– – ﹤0.01% 7065
2018
Q1 		$356K Buy
3,566
+696
+24% +$75K ﹤0.01% 6464
2017
Q4 		$269K Sell
2,870
-11,309
-80% -$1.07M ﹤0.01% 6634
2017
Q3 		$1.44M Buy
14,179
+3,024
+27% +$264K ﹤0.01% 3814
2017
Q2 		$854K Buy
11,155
+8,380
+302% +$705K ﹤0.01% 4324
2017
Q1 		$239K Sell
2,775
-25,357
-90% -$1.83M ﹤0.01% 6232
2016
Q4 		$1.81M Buy
28,132
+21,758
+341% +$1.34M ﹤0.01% 3074
2016
Q3 		$412K Buy
6,374
+120
+2% +$6.76K ﹤0.01% 5164
2016
Q2 		$347K Buy
+6,254
New +$315K ﹤0.01% 5007
2015
Q3 		– Sell
-10,511
Closed -$541K – 9010
2015
Q2 		$541K Buy
+10,511
New +$558K ﹤0.01% 4832

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors's LKFT Position: Q1 2026 in Review

Citadel Advisors increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 39% in Q1 2026, buying an estimated $1.16M and bringing the position to 124,428 shares worth $3.73M. The position accounts for ﹤0.01% of the portfolio, ranked #4844.

Citadel Advisors first reported a position in LKFT in Q2 2015 and has held it in 38 quarters since. The position peaked at $31.2M in Q2 2021. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • Citadel Advisors held 124,428 shares of Lakefront Biotherapeutics American Depositary Shares worth $3.73M as of Q1 2026.
  • Citadel Advisors bought 35,032 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $1.16M.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4844 holding.
  • Citadel Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and has held it in 38 quarters since.
  • Citadel Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $31.2M in Q2 2021.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.